Title: The Innovations of Ziad S Kawar
Introduction
Ziad S Kawar is an accomplished inventor based in the United States. He has made significant contributions to the field of biomedical research, particularly in the development of antibodies that target P-selectin. His work has implications for treating various inflammatory and thrombotic disorders.
Latest Patents
Ziad S Kawar currently holds 0 patents. However, his notable patent involves the use of anti-P-selectin antibodies. These antibodies specifically bind to P-selectin, blocking the binding of PSGL-1 and causing the dissociation of preformed P-selectin/PSGL-1 complexes. This discovery highlights a previously unrecognized antibody binding domain of P-selectin, which can be targeted for therapeutic purposes.
Career Highlights
Throughout his career, Ziad has worked with prominent organizations such as the Oklahoma Medical Research Foundation and Selexys Pharmaceuticals Corporation. His research has focused on the dual functionality of anti-P-selectin antibodies, which can block PSGL-1 binding and promote the dissociation of complexes. This innovative approach has the potential to advance treatments for acute and chronic inflammatory conditions.
Collaborations
Ziad has collaborated with notable colleagues, including Scott A Rollins and Richard Alvarez. Their combined expertise has contributed to the advancement of research in the field of antibody development.
Conclusion
Ziad S Kawar's work in the development of anti-P-selectin antibodies represents a significant advancement in biomedical research. His contributions have the potential to lead to new treatments for various inflammatory disorders.